Navigation Links
NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman Alleges that NuvaRing Use Caused Her to Develop Serious Blood Clot Disorder, Reports Alonso Krangle
Date:8/11/2013

New York, NY (PRWEB) August 12, 2013

Alonso Krangle’s attorneys have recently filed a NuvaRing lawsuit against Organon and others on behalf of a woman from South Carolina. This case (Case No. 2:13-cv-02932-SDW-MCA) was filed on May 8, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc. and Merck & Co., Inc.

The NuvaRing lawsuit complaint for this case explains that the same month, the plaintiff began using the Nuvaring, she began experiencing pain in her lower right leg and saw her doctor for an official diagnosis. After undergoing a venous duplex scan, the plaintiff was informed that she had developed deep vein thrombosis (a condition in which blood clots lodge in and block blood flow through the body’s deep veins). Following this diagnosis, the plaintiff was hospitalized for three days and was placed on anticoagulation therapy, including Lovenox and Coumadin. While the plaintiff had to continue this drug therapy ever since she has been released from the hospital, she has also had to undergo regular follow-up care to monitor her health.

Alonso Krangle’s experienced NuvaRing lawsuit attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

While this NuvaRing lawsuit contends that use of NuvaRing caused the plaintiff to develop deep vein thrombosis, this case also alleges that Organon and the other defendants were aware of but failed to warn the public about the fact that NuvaRing is linked to a higher risk of blood clot-related complications than oral contraceptives. Additionally, this NuvaRing lawsuit contends that the defendants marketed NuvaRing as a safe and effective contraceptive without warning women about the potentially serious risks of reportedly linked to NuvaRing use.

Researchers Link NuvaRing to Serious Blood Clot Complications

The link between NuvaRing use and the development of serious blood clot disorders like deep vein thrombosis and pulmonary embolism has been reported by many medical researchers within recent years. Specifically, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots when compared to the risk associated with older birth control pills.
[ http://www.nejm.org/doi/full/10.1056/NEJMoa1111840 June 14, 2012 ]

Another study published in the May 2012 British Medical Journal reported that women’s risk of developing blood clots increased by more than 6 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
[ http://www.bmj.com/content/344/bmj.e2990"; Published 10 May 2012 ]

In line with the findings of these studies is information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects associated with NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, more than 30 percent of women who reported NuvaRing complications had to be hospitalized due to the severity of their injuries, and approximately 3 percent of NuvaRing complications resulted in death.
[ http://adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING

About Alonso Krangle LLP And Filing A NuvaRing Lawsuit

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11015112.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
2. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
3. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
4. NuvaRing Blood-Clotting Victims Still Eligible to File Lawsuits Through Resource4thePeople
5. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
6. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
7. NuvaRing Blood-Clotting Claims Now Being Investigated by Resource4thePeople Attorneys
8. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
9. 2013 NuvaRing Blood-Clotting Allegations Inquiries Eligible for Review by Resource4thePeople Attorneys
10. Rescheduling of First NuvaRing Lawsuit Trials in State, Federal NuvaRing Lawsuit Litigation, Reports Wright & Schulte LLC
11. First NuvaRing Lawsuits in State, Federal NuvaRing Litigations Set to Head to Trial Later This Year, Alonso Krangle LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: